Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
Because life expectancy and the prevalence of risk factors such as hypertension, obesity and diabetes are rising globally, heart failure (HF) is growing into a major health problem. Impairment of left ...
To distinguish the two groups, you really need to see the echocardiogram and the measurement of LVEF. "That doesn't preclude that these medications could have a longer-term benefit—maybe the ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with COVID-19 had impaired left ventricular ...
Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results